InMed Pharmaceuticals Files 8-K

Ticker: INM · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1728328

Sentiment: neutral

Topics: disclosure, regulatory

TL;DR

InMed Pharma filed an 8-K, standard disclosure, no major news yet.

AI Summary

InMed Pharmaceuticals Inc. filed an 8-K on January 21, 2025, reporting a current event. The filing does not contain specific financial details or significant business updates, but rather serves as a notification of a reportable event.

Why It Matters

This filing indicates a formal disclosure event by InMed Pharmaceuticals Inc. to the SEC, which could relate to various corporate actions or regulatory requirements.

Risk Assessment

Risk Level: low — The filing is a routine 8-K without specific financial or operational disclosures that would immediately impact risk.

Key Players & Entities

FAQ

What is the specific event being reported in this 8-K filing?

The filing itself does not specify the exact event, only that it is a 'Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934' and is being filed as of January 21, 2025.

Does this 8-K filing contain any financial statements or exhibits?

The filing lists 'Financial Statements and Exhibits' under 'ITEM INFORMATION', but the content of these is not detailed in the provided header information.

What is the Commission File Number for InMed Pharmaceuticals Inc.?

The Commission File Number for InMed Pharmaceuticals Inc. is 001-39685.

Where are InMed Pharmaceuticals Inc.'s principal executive offices located?

InMed Pharmaceuticals Inc.'s principal executive offices are located at Suite 1445 - 885 W. Georgia Street, Vancouver, B.C., Canada.

What is the standard industrial classification for InMed Pharmaceuticals Inc.?

The Standard Industrial Classification for InMed Pharmaceuticals Inc. is PHARMACEUTICAL PREPARATIONS [2834].

Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-21 10:54:19

Filing Documents

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated January 21, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)______________ 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: January 21, 2025 By: /s/ Eric A Adams Eric A Adams President & CEO 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing